AS

Anand Singh

Director Director DIN 08478875
DIN 08478875 First appointment Jun 2019 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Jun 2019
Shareholding value β€’β€’β€’β€’ Premium profile

About Anand Singh

Data last updated:

Anand Singh was a Director at Aclaris Pharmaceuticals Private Limited (2020–2022) and Director at Kdi Pharma Private Limited (from 2019). The companies operate in Pharma.

DIN 08478875
Primary Designation Director
Industry Pharma
First Appointment 12 Jun 2019
Oldest Company Age 7 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director10 Aug 20202020Active
Kdi Pharma Private Limited U52311UP2019PTC117916
Director12 Jun 20192019Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Kdi Pharma Private Limited
Aclaris Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Anand Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anand Singh

Anand Singh was first appointed on 12 Jun 2019 as Director at Kdi Pharma Private Limited. The most recent appointment on record is 10 Aug 2020 at Aclaris Pharmaceuticals Private Limited.

Anand Singh held 2 earlier board appointments: Aclaris Pharmaceuticals Private Limited (Director, 10 Aug 2020 to 30 Jul 2022); Kdi Pharma Private Limited (Director, from 12 Jun 2019).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available